Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.53 |
| ▸ | CASR | P41180 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | SELL | P14151 | 2/20 | 0.50 |
| ▸ | SELP | P16109 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SELE | P16581 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1416836 | 0.98 | ALDH1A1 (0.61) | ALDH1A1MAPTAKR1C3CASRL3MBTL1 | |
| SCHEMBL11783613 | 0.85 | MAPT (0.47) | ALDH1A1MAPTAKR1C3CASRL3MBTL1 | |
| SCHEMBL6235537 | 0.85 | ALDH1A1 (0.58) | ALDH1A1MAPTL3MBTL1KDM4ENPC1 | |
| SCHEMBL9308545 | 0.85 | PRKCI (0.49) | ALDH1A1MAPTAKR1C3CASRNPC1 | |
| Hydrochloric Acid SCHEMBL28054067 | 0.83 | ALDH1A1 (0.56) | ALDH1A1MAPTL3MBTL1KDM4ENPC1 | |
| SCHEMBL7772145 | 0.82 | AKR1C3 (0.54) | ALDH1A1MAPTAKR1C3CASRL3MBTL1 | |
| SCHEMBL1002161 | 0.82 | MAPT (0.69) | ALDH1A1MAPTL3MBTL1KDM4ENPC1 | |
| SCHEMBL11965655 | 0.81 | PLAU (0.47) | ALDH1A1MAPTTSHR | |
| SCHEMBL26292488 | 0.81 | AKR1C3 (0.53) | ALDH1A1MAPTAKR1C3CASRL3MBTL1 | |
| Hydrochloric Acid SCHEMBL6231788 | 0.80 | CYP2C9 (0.55) | ALDH1A1MAPTL3MBTL1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492193-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | FONDAZIONE INSTITUTO ITALIANO DI TECNOLOGIA (IT) | 2025-12-09 | — | — | US | disclosed |
| CN-112839928-B | Synthetic method for preparing 3- [ 5-amino-4- (3-cyanobenzoyl) -pyrazole compound | 梅里奥生物制药1有限公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20230212157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | ISTITUTO GIANNINA GASLINI (IT) | 2023-07-06 | — | — | US | disclosed |
| EP-3596067-B1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2023-06-07 | — | — | EP | disclosed |
| US-11649213-B2 | Synthetic method for the preparation of a 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol compound | MEREO BIOPHARMA 1 LIMITED (GB) | 2023-05-16 | — | — | US | disclosed |
| US-11649213-B2 | Synthetic method for the preparation of a 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol compound | MEREO BIOPHARMA 1 LIMITED (GB) | 2023-05-16 | — | — | US | disclosed |
| US-11649213-B2 | Synthetic method for the preparation of a 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol compound | MEREO BIOPHARMA 1 LIMITED (GB) | 2023-05-16 | — | — | US | disclosed |
| EP-3856721-B1 | SYNTHETIC METHOD FOR THE PREPARATION OF A 3-[5-AMINO-4-(3-CYANOBENZOYL)-PYRAZOL COMPOUND | MEREO BIOPHARMA 1 LTD (GB) | 2023-03-29 | — | — | EP | disclosed |
| EP-3856721-B1 | SYNTHETIC METHOD FOR THE PREPARATION OF A 3-[5-AMINO-4-(3-CYANOBENZOYL)-PYRAZOL COMPOUND | MEREO BIOPHARMA 1 LTD (GB) | 2023-03-29 | — | — | EP | disclosed |
| US-11597723-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | FONDAZIONE ISTITUTO ITALIANO DI TECHNOLOGIA (IT) | 2023-03-07 | — | — | US | disclosed |
| EP-1887003-A1 | 3-[4-HETEROCYCLYL -1,2,3-TRIAZOL-1-YL]-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20070142371-A1 | Anti-Cytokine Heterocyclic Compounds | COGAN DEREK | 2007-06-21 | — | — | US | disclosed |
| US-7214802-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| EP-1725544-A1 | 3-[4-HETEROCYCLYL-1,2,3-TRIAZOL-1-YL]-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-11-29 | — | — | EP | disclosed |
| CN-1832928-A | 5-membered heterocycle-based p38 kinase inhibitors | NOVARTIS AG (CH) | 2006-09-13 | — | — | CN | disclosed |
| US-20060100204-A1 | Heterocyclic-substituted benzamide derivatives, e.g., benzyl [2-(4-{1-[5-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenylcarbamoyl)-2-methyl-phenyl]-1H-1,2,3-triazol-4-yl}-2-phenyl-2H-pyrazol-3-yl)-ethyl]-carbamate; inhibit production of cytokines; useful for treating chronic inflammatory disease. | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-05-11 | — | — | US | disclosed |
| US-20060079519-A1 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-04-13 | — | — | US | disclosed |
| WO-2005090333-A1 | 3-‘4-HETEROCYCLYL -1,2,3,-TRIAZOL-1-YL!-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005007632-A1 | SUBSTITUTED PYRIDAZINONES AS INHIBITORS OF P38 | PHARMACIA CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20050020594-A1 | Substituted pyridazinones | PHARMACIA CORPORATION | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100204-A1 | Heterocyclic-substituted benzamide derivatives, e.g., benzyl [2-(4-{1-[5-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenylcarbamoyl)-2-methyl-phenyl]-1H-1,2,3-triazol-4-yl}-2-phenyl-2H-pyrazol-3-yl)-ethyl]-carbamate; inhibit production of cytokines; useful for treating chronic inflammatory disease. | NFKBIA, CHUK, IL1B | ALDH1A1 974/4885MAPT 2580/4885AKR1C3 2135/4885 |
| US-20230212157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCC5, ABCC1 | ALDH1A1 1738/4885MAPT 4663/4885AKR1C3 2052/4885 |
| US-11649213-B2 | Synthetic method for the preparation of a 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol compound | SLC1A5, BCAT2, CYP3A5 | ALDH1A1 2990/4885MAPT 3799/4885AKR1C3 511/4885 |
| US-20070142371-A1 | Anti-Cytokine Heterocyclic Compounds | TNF, IL6, IL1A | ALDH1A1 278/4885MAPT 3851/4885AKR1C3 687/4885 |
| US-12492193-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | CFTR, ABCC5, ABCC1 | ALDH1A1 1738/4885MAPT 4663/4885AKR1C3 2052/4885 |
| US-20060079519-A1 | Anti-cytokine heterocyclic compounds | TNF, IL6, IL1A | ALDH1A1 278/4885MAPT 3851/4885AKR1C3 687/4885 |
| US-11597723-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | CFTR, ABCC5, ABCC3 | ALDH1A1 1717/4885MAPT 4662/4885AKR1C3 2010/4885 |
| US-20050020594-A1 | Substituted pyridazinones | MAP4K2, MAPK6, MAP3K6 | ALDH1A1 2217/4885MAPT 1544/4885AKR1C3 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.